Christian Nasr, MD
Endocrinology, Diabetes & Metabolism · Cleveland, OHNPI 1760448906
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Amgen at 31.0% of the total. Reporting peaked in 2021 at $12,487 and has fallen 72.9% since, to $3,384 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $480.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$14K
- Siemens Medical Solutions USA, Inc.$11K
- Shire North American Group Inc$9K
- Exelixis Inc.$9K
- Nevro Corp.$1K
- Lilly USA, LLC$331
- plus $2K from 20 others
Across 3 payments — averaging $53,052 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Siemens Medical Solutions USA, Inc.$159K
What the payments were for
- Consulting fees$26,24457%
- Speaking & faculty fees$14,83832%
- Travel & lodging$9462%
- Food & beverage$3,9889%
- Education$810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 29 | $14,289 |
| Siemens Medical Solutions USA, Inc. | 2 | $10,594 |
| Shire North American Group Inc | 10 | $8,946 |
| Exelixis Inc. | 6 | $8,837 |
| Nevro Corp. | 2 | $1,400 |
| Lilly USA, LLC | 7 | $331 |
| Medtronic | 3 | $298 |
| Insulet Corporation | 5 | $230 |
| Cequr Corporation | 1 | $225 |
| Novo Nordisk | 7 | $202 |
| Ascendis Pharma Endocrinology Inc | 1 | $120 |
| AbbVie | 1 | $111 |
| Ascensia Diabetes Care US Inc. | 1 | $98 |
| Dexcom, Inc. | 3 | $70 |
| Xeris Pharmaceuticals, Inc. | 3 | $59 |
| Amryt Pharma Holdings Ltd | 1 | $55 |
| Abbott | 4 | $55 |
| Boehringer Ingelheim | 2 | $49 |
| Mannkind Corporation | 1 | $19 |
| Advanced Accelerator Applications | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$13,804
- Cabozantinib$5,775
- Atellica IM 1300 Analyzer$5,625
- Atellica$4,969
- Cabometyx$2,975
- Senza Spinal Cord Stimulation System$1,400
- MINIMED 780G$281
- CeQur Simplicity$225
- RETEVMO$122
- Yorvipath$120
- Synthroid$111
How this compares
$46,097 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 19 | $94,875 |
| OzempicSemaglutide | 64 | $72,568 |
| MounjaroTirzepatide | 49 | $58,798 |
| TrulicityDulaglutide | 36 | $53,476 |
| JardianceEmpagliflozin | 28 | $40,004 |
| Levothyroxine Sodium | 538 | $37,363 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $14,000 |
| JanuviaSitagliptin Phosphate | 12 | $12,825 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $11,230 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $10,458 |
| TradjentaLinagliptin | 15 | $9,457 |
| SynthroidLevothyroxine Sodium | 72 | $6,721 |
| Novolog FlexpenInsulin Aspart | 31 | $6,537 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 16 | $5,582 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $5,231 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro, Trulicity, Humalog | $331 | $208,421118 claims |
| Novo NordiskOzempic | $202 | $72,56864 claims |
| Boehringer IngelheimJardiance, Tradjenta | $49 | $49,46243 claims |
| MerckJanuvia | $12 | $12,82512 claims |
| AbbVieSynthroid | $111 | $6,72172 claims |
| Sanofi-aventis U.S. LLCLantus | $16 | $2,19816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Cleveland
- Kevin PantaloneCleveland$1.2M
- Allan KennedyCleveland$245K
- Adi MehtaCleveland$120K
- Amir HamrahianCleveland$59K
- Bartolome BurgueraCleveland$52K
- Robert ZimmermanCleveland$45K
- Mario SkugorCleveland$45K
- Bahauddin ArafahCleveland$25K
- Divya Yogi-MorrenCleveland$24K
- Vinni MakinCleveland$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.